Natural Capsules Latest Share Price (NATCAPSUQ)
TODAY IN ONE LINE
NATCAPSUQ rose 1.3% on above-average volume (4.6x avg), in line with Nifty's 0.5% move, supported by recent strong earnings.
With a market cap of ₹174.96 Cr., it trades at a P/E of -8.15. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Natural Capsules flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 51.0% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Natural Capsules News
What changed recently?
Recent events, corporate actions, and announcements.
Natural Capsules Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Natural Capsules Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Natural Capsules Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Natural Capsules Limited — derived from the latest tape, not yesterday's close.
Natural Capsules Limited last traded at ₹166.88 with an intraday range of ₹163.28–₹168.3 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹166.88| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 179.07 | +12.19 | +7.30% |
| R3 | 174.05 | +7.17 | +4.29% |
| R2 | 171.17 | +4.29 | +2.57% |
| R1 | 169.03 | +2.15 | +1.29% |
| PIVOT | 166.15 | -0.73 | -0.44% |
| CURRENT | 166.88 | — | — |
| S1 | 164.01 | -2.87 | -1.72% |
| S2 | 161.13 | -5.75 | -3.44% |
| S3 | 158.99 | -7.89 | -4.73% |
| S4 | 153.97 | -12.91 | -7.74% |
NATCAPSUQ is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹164.72–₹167.19
Trading Above opening range, showing Bullishness
Natural Capsules Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Natural Capsules Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Natural Capsules Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹174.96 Cr. and reported EPS of ₹-23.84.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 169 | 187 ▲ 10.6% |
| Sales Growth YoY %Derived | 8.87% | 10.64% |
| Other Income | 1 | 2 ▲ 146.1% |
| Total Income | 170 | 189 ▲ 11.2% |
| 85 | 102 ▲ 20.5% | |
| Gross ProfitDerived | 84 | 85 ▲ 0.7% |
| Gross Margin %Derived | 49.82% | 45.33% |
| 67 | 86 ▲ 29.4% | |
| EBITDA (Operating Profit)Derived | 18 | -2 ▼ 108.9% |
| OPM %Derived | 10.35% | -0.83% |
| 15 | 28 ▲ 82.0% | |
| Profit Before Tax (PBT) | 3 | -28 ▼ 1100.4% |
| 2 | -3 ▼ 249.8% | |
| Effective Tax %Derived | 77.88% | 11.66% |
| Total Profit for Period | 1 | -25 ▼ 4094.7% |
| Less: Non-controlling Interests | — | -8 |
| Net Profit (Owner's PAT)Derived | 1 | -17 ▼ 2865.4% |
| Net Profit Margin %Derived | 0.36% | -9.12% |
| PAT Growth YoY %Derived | -88.88% | -2,865.40% |
| Earnings Per Share (EPS ₹) | 0.60 | -16.44 ▼ 2840.0% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.4% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 98.6% |
| Total Expenses (incl. D&A & Interest) | 167 | 217 ▲ 29.8% |
| Material Cost % of RevenueDerived | 51.35% | 55.14% |
| Employee Cost % of RevenueDerived | 8.35% | 11.22% |
| Other Cost % of RevenueDerived | 31.12% | 34.94% |
| Interest Coverage (x)Derived | 1.33x | -1.71x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 60 | 62 ▲ 3.0% | 80 ▲ 29.2% | 135 ▲ 69.9% | 172 ▲ 27.6% | 155 ▼ 9.8% | 169 ▲ 8.9% | 187 ▲ 10.6% | |
| Sales Growth YoY %Derived | — | 2.98% | 29.16% | 69.88% | 27.62% | -9.83% | 8.87% | 10.64% | |
| Other Income | 1 | 1 ▼ 28.0% | 1 ▼ 23.2% | 1 ▲ 38.4% | 1 ▼ 43.6% | 2 ▲ 240.4% | 1 ▼ 63.7% | 2 ▲ 146.1% | |
| Total Income | 61 | 63 ▲ 2.3% | 80 ▲ 28.4% | 136 ▲ 69.6% | 173 ▲ 27.1% | 157 ▼ 9.0% | 170 ▲ 8.0% | 189 ▲ 11.2% | |
27 | 28 ▲ 5.7% | 37 ▲ 33.5% | 60 ▲ 59.8% | 79 ▲ 31.6% | 79 ▼ 0.0% | 85 ▲ 7.9% | 102 ▲ 20.5% | ||
| Gross ProfitDerived | 33 | 34 ▲ 0.8% | 42 ▲ 25.5% | 75 ▲ 78.9% | 94 ▲ 24.5% | 77 ▼ 18.1% | 84 ▲ 9.8% | 85 ▲ 0.7% | |
| Gross Margin %Derived | 55.65% | 54.47% | 52.92% | 55.73% | 54.35% | 49.38% | 49.82% | 45.33% | |
29 | 28 ▼ 1.2% | 31 ▲ 10.4% | 50 ▲ 60.2% | 60 ▲ 19.3% | 57 ▼ 4.5% | 67 ▲ 17.5% | 86 ▲ 29.4% | ||
| EBITDA (Operating Profit)Derived | 5 | 5 ▲ 13.0% | 11 ▲ 105.8% | 25 ▲ 132.2% | 34 ▲ 34.6% | 20 ▼ 41.7% | 18 ▼ 12.0% | -2 ▼ 108.9% | |
| OPM %Derived | 7.86% | 8.63% | 13.75% | 18.79% | 19.82% | 12.81% | 10.35% | -0.83% | |
3 | 5 ▲ 53.8% | 7 ▲ 40.3% | 7 ▲ 2.0% | 11 ▲ 51.7% | 14 ▲ 29.9% | 15 ▲ 11.8% | 28 ▲ 82.0% | ||
| Profit Before Tax (PBT) | 2 | 1 ▼ 33.5% | 9 ▲ 568.6% | 19 ▲ 111.7% | 24 ▲ 24.4% | 8 ▼ 66.6% | 3 ▼ 65.3% | -28 ▼ 1100.4% | |
0 | 1 ▲ 264.3% | 2 ▲ 341.2% | 5 ▲ 143.1% | 7 ▲ 19.7% | 3 ▼ 61.8% | 2 ▼ 13.1% | -3 ▼ 249.8% | ||
| Effective Tax %Derived | 6.80% | 37.23% | 24.56% | 28.21% | 27.16% | 31.06% | 77.88% | 11.66% | |
| Total Profit for Period | 2 | 1 ▼ 55.2% | 7 ▲ 703.5% | 14 ▲ 101.4% | 18 ▲ 26.2% | 6 ▼ 68.4% | 1 ▼ 88.9% | -25 ▼ 4094.7% | |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | -8 | |
| Net Profit (Owner's PAT)Derived | 2 | 1 ▼ 55.2% | 7 ▲ 703.5% | 14 ▲ 101.4% | 18 ▲ 26.2% | 6 ▼ 68.4% | 1 ▼ 88.9% | -17 ▼ 2865.4% | |
| Net Profit Margin %Derived | 3.21% | 1.40% | 8.69% | 10.31% | 10.19% | 3.57% | 0.36% | -9.12% | |
| PAT Growth YoY %Derived | — | -55.21% | 703.49% | 101.45% | 26.22% | -68.41% | -88.88% | -2,865.40% | |
| Earnings Per Share (EPS ₹) | 2.05 | 0.92 ▼ 55.1% | 7.39 ▲ 703.3% | 14.89 ▲ 101.5% | 18.79 ▲ 26.2% | 5.94 ▼ 68.4% | 0.60 ▼ 89.9% | -16.44 ▼ 2840.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 10.6% | 1 ▲ 0.4% | |
| Other Comprehensive Income (Net of Tax) | — | 0 | -0 ▼ 400.0% | -0 ▼ 233.3% | -0 ▲ 70.0% | 0 ▲ 533.3% | -0 ▼ 250.0% | -0 ▲ 98.6% | |
| Total Expenses (incl. D&A & Interest) | 59 | 61 ▲ 3.6% | 71 ▲ 16.3% | 117 ▲ 64.2% | 149 ▲ 27.5% | 149 ▲ 0.3% | 167 ▲ 11.9% | 217 ▲ 29.8% | |
| Material Cost % of RevenueDerived | 38.14% | 45.35% | 45.40% | 41.49% | 48.37% | 54.05% | 51.35% | 55.14% | |
| Employee Cost % of RevenueDerived | 10.61% | 11.35% | 10.12% | 7.12% | 6.22% | 7.96% | 8.35% | 11.22% | |
| Other Cost % of RevenueDerived | 37.19% | 34.49% | 29.05% | 29.81% | 28.31% | 28.61% | 31.12% | 34.94% | |
| Interest Coverage (x)Derived | 4.05x | 1.55x | 17.89x | 10.38x | 7.91x | 2.19x | 1.33x | -1.71x |
Natural Capsules segment analysis : revenue and profit mix.
Disclosed business segments at Natural Capsules with their share of revenue and profit, switchable between consolidated and standalone reporting.
Natural Capsules discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Natural Capsules Limited.
Our AI distills the core fundamental drivers supporting Natural Capsules Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Natural Capsules Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM revenue growth 30% YoY demonstrates robust top-line expansion in pharma packaging sector.
Operating cash flow ₹36.16 Cr shows strong cash generation despite accounting losses.
Promoter holding 51.04% signals strong founder commitment and aligned long-term interests.
Low beta 0.3427 indicates lower systematic risk relative to broader market volatility.
Price-to-book 0.46x suggests potential undervaluation versus tangible asset base.
Key Risks.
Operating margin -0.83% and net margin -13.17% reflect severe core business unprofitability.
Latest quarterly EPS -₹23.84 with PAT -₹3.45 Cr signals extreme recent earnings deterioration.
ROE -7.30% and ROCE -4.76% indicate persistent capital inefficiency and poor returns.
Total debt ₹115 Cr with net debt ₹97.13 Cr exposes elevated financial risk on negative profitability.
Zero dividend yield and zero institutional ownership limit appeal to income-seeking investors.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Natural Capsules Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Natural Capsules Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Natural Capsules Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Natural Capsules Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Natural Capsules Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Natural Capsules Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Natural Capsules Limited stood at 64.7% of traded volume, against a 20-day average of 68.4%.
Natural Capsules announcements: results, concalls, ratings, M&A.
Filings Natural Capsules sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Natural Capsules files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 97 documents below.
Copy of Newspaper Publication
Natural Capsules Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Natural Capsules Limited has informed the Exchange about Copy of Newspaper Publication
Record Date
Natural Capsules Limited has informed the Exchange that Record date for the purpose of Meeting is 02-Sep-2026.
Shareholders meeting
Natural Capsules Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on September 09, 2026
Disclosure of material issue
Natural Capsules Limited has informed regarding Disclosure of material issue
Investor decks & rating reports.
Natural Capsules dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Natural Capsules has declared, sequenced by announce and record date.
Natural Capsules corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Natural Capsules Limited: business, sector, key facts.
What Natural Capsules Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Natural Capsules Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NATCAPSUQ, BSE: 524654.
Natural Capsules Limited, operating under the assumed name NATCAPSUQ (although this name isn't explicitly stated in the provided text), is a prominent manufacturer and supplier of hard gelatin and cellulose capsule shells. Their primary market encompasses both India and international locations, showcasing a robust global presence in the pharmaceutical packaging industry. The company's offerings cater to a diverse range of customer needs and regulatory requirements.
The company’s product portfolio features a wide variety of capsule shells, demonstrating a commitment to providing options for diverse applications. This includes bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE)-free gelatin, which addresses critical safety concerns in pharmaceutical manufacturing. Additionally, they offer shiny gelatin for enhanced visual appeal, sodium lauryl sulfate-free gelatin for specific formulation needs, and halal-certified gelatin for compliance with religious dietary regulations. Further options include fast-release gelatin for expedited drug delivery and printed gelatin/cellulose capsules for branding and product identification. For customers seeking vegetarian alternatives, the company provides suitable cellulose capsule shells, and enteric capsules are also part of their extensive product line.
Beyond the production and sale of capsule shells, Natural Capsules Limited extends its services into pharmaceutical dosage form formulation. This vertical integration allows them to offer a comprehensive solution to clients, moving beyond simply supplying packaging materials to providing assistance in the complete creation of capsule-based medications. This aspect of their business suggests a deeper understanding of the pharmaceutical industry and the requirements for effective drug delivery.
Established in 1993 and headquartered in Bengaluru, India, Natural Capsules Limited boasts a significant history within the sector. Their export activities highlight their success in reaching international markets and competing effectively on a global scale. The company's continued operation and diverse product offerings suggest a strong market position and a commitment to innovation within the pharmaceutical packaging industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Natural Capsules Limited (NATCAPSUQ).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Natural Capsules Limited (NATCAPSUQ)?
The current share price of Natural Capsules Limited (NATCAPSUQ) is ₹166.88. Today, the stock has gained by ₹2.20 (1.34%), trading in a range of ₹163.28 to ₹168.30. The stock opened at ₹165.17 with a trading volume of 60,568 shares.
02Is Natural Capsules Limited stock a good investment for long-term?
Natural Capsules Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹174.96 Cr., P/E ratio of -8.15, ROE of -7.3%, and ROCE of -4.76%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Natural Capsules Limited stock?
The 52-week high price of Natural Capsules Limited (NATCAPSUQ) is ₹296.00, while the 52-week low is ₹136.36. Currently trading at ₹166.88, the stock is 22.38% above its 52-week low and 43.62% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Natural Capsules Limited stock at the current price?
Whether to buy Natural Capsules Limited stock at ₹166.88 depends on multiple factors. The stock is currently trading with a P/E ratio of -8.15 and P/B ratio of 0.69. Today's performance shows a gain of 1.34%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Natural Capsules Limited and when is the next dividend?
Natural Capsules Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹166.88, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Natural Capsules Limited?
Natural Capsules Limited's key financial metrics include: P/E Ratio: -8.15, P/B Ratio: 0.69, ROE: -7.3%, ROCE: -4.76%, Dividend Yield: 0%, EPS: ₹-23.84, Book Value: ₹310.07, and Debt-to-Equity: 0.49. The company's market cap stands at ₹174.96 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Natural Capsules Limited stock performing today in the market?
Natural Capsules Limited stock opened at ₹165.17 and is currently trading at ₹166.88, showing a gain of ₹2.20 (1.34%). The intraday high is ₹168.30 and low is ₹163.28. The trading volume stands at 60,568 shares, indicating moderate market participation today.
08What is the P/E ratio of Natural Capsules Limited and what does it indicate?
Natural Capsules Limited has a Price-to-Earnings (P/E) ratio of -8.15, which means investors are willing to pay -8.15 for every ₹1 of earnings. With an EPS of ₹-23.84, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Natural Capsules Limited (NATCAPSUQ) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.